T2000 in Essential Tremor - Open Label Continuation
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric Acid) in Patients With Essential Tremor: An Open-Label Dose Continuation Study|
- Effect of treatment on tremor will be measured by a tremor scale as well as by assessment of functional activity with specific tasks. [ Time Frame: Up to 18 months ] [ Designated as safety issue: No ]
- Safety parameters including neurological examination, blood tests and EKG will be monitored throughout the treatment period and during withdrawal of the medication. [ Time Frame: Up to 18 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||August 2007|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
T2000 at 600-1000 mg daily
T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
Essential tremor (ET) is a common form of involuntary shaking not related to Parkinson's disease. The medications that are currently used to treat ET work in a small proportion of patients and provide only partial improvement in symptoms. Use of these current medications is also limited by side-effects in many patients.
T2000 is a medication currently under development for the treatment of essential tremor. Although T2000 is a new medication, it belongs to a class of medications that has been used for many years for the treatment of a variety of medical conditions. In previous studies, T2000 appeared to be effective in controlling symptoms of ET and some patients with severe ET had major improvements in tremor. In some patients T2000 was well tolerated for periods up to 5 months and the minimal side-effects seen were those that would be expected for medications in this class.
The current study will evaluate the safety and efficacy of T2000 in patients with moderate to severe essential tremor. Patients will receive doses of T2000 beginning at 600 mg a day, followed by 800 mg a day and up to 1000 mg a day. The total duration of treatment will be 18 months. Patient's tremor and neurological examination will be monitored throughout the study.
|London Health Sciences Center|
|London, Ontario, Canada, N6A 5A5|
|Parkinson's Disease and Movement Disorders Clinic - The Ottawa Hospital: Civic Campus|
|Ottawa, Ontario, Canada, K1Y 4E9|
|Movement Disorder Clinic: University Health Network; Toronto Western Hospital|
|Toronto, Ontario, Canada, M5R 2N5|
|Principal Investigator:||Anthony Lang, MD FRCPC||University Health Network - Toronto Western Hospital|